GenOway shows growth of 15% in the first half of 2024

genOway, specializing in the design of predictive preclinical solutions, has published its turnover for the first half of 2024. The company achieved a turnover of 10.7 million euros, compared to 9.3 million euros in the same half-year in 2023, marking organic growth of 15%.

This performance is in line with the objective of annual growth similar to that of 2023. genOway continues to generate double-digit organic growth for the fifth consecutive year, mainly thanks to the development of sales of Catalog models.

The company has decided to group the Catalog and Custom activities, now fungible, to respond more effectively to changing customer demand.

The Route50+ strategic plan targets annual growth of 20%, with a target of €50 million in sales by 2028, while maintaining an EBITDA margin above 15%.